Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective cut by HC Wainwright from $61.00 to $60.00 in a report issued on Wednesday morning, FlyOnTheWall reports.
Other research analysts have also issued reports about the stock. Piper Sandler raised shares of Halozyme Therapeutics from a neutral rating to an overweight rating and set a $46.00 price objective for the company in a report on Wednesday, May 10th. The Goldman Sachs Group downgraded shares of Halozyme Therapeutics from a buy rating to a neutral rating and increased their price target for the company from $43.00 to $45.00 in a report on Monday, July 24th. TheStreet cut shares of Halozyme Therapeutics from a b- rating to a c+ rating in a research report on Tuesday, June 20th. Finally, StockNews.com began coverage on shares of Halozyme Therapeutics in a research note on Thursday, May 18th. They set a hold rating on the stock. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average target price of $54.27.
Check Out Our Latest Analysis on HALO
Halozyme Therapeutics Trading Down 0.6 %
Insider Activity at Halozyme Therapeutics
In other news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $40.43, for a total transaction of $404,300.00. Following the completion of the sale, the senior vice president now directly owns 141,911 shares of the company’s stock, valued at approximately $5,737,461.73. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders sold 30,000 shares of company stock valued at $1,191,200. 2.40% of the stock is owned by insiders.
Institutional Investors Weigh In On Halozyme Therapeutics
Several large investors have recently added to or reduced their stakes in HALO. ArrowMark Colorado Holdings LLC bought a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $44,170,000. Artisan Partners Limited Partnership grew its holdings in Halozyme Therapeutics by 16.5% during the 4th quarter. Artisan Partners Limited Partnership now owns 7,140,953 shares of the biopharmaceutical company’s stock valued at $406,320,000 after buying an additional 1,013,061 shares in the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $53,957,000. Macquarie Group Ltd. increased its position in Halozyme Therapeutics by 22.8% during the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock valued at $122,226,000 after buying an additional 595,220 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Halozyme Therapeutics in the second quarter worth about $17,594,000. Hedge funds and other institutional investors own 92.93% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Further Reading
- Five stocks we like better than Halozyme Therapeutics
- How Can Investors Use the Dogs of the Dow Strategy?
- MarketBeat Week in Review – 8/7 – 8/11
- The How and Why of Investing in Large-Cap Stocks
- 3 Retailers To Watch Closely Next Week
- The Significance of Brokerage Rankings in Stock Selection
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
